ECSP10010538A - Preparacion solida de desintegracion oral - Google Patents

Preparacion solida de desintegracion oral

Info

Publication number
ECSP10010538A
ECSP10010538A EC2010010538A ECSP10010538A ECSP10010538A EC SP10010538 A ECSP10010538 A EC SP10010538A EC 2010010538 A EC2010010538 A EC 2010010538A EC SP10010538 A ECSP10010538 A EC SP10010538A EC SP10010538 A ECSP10010538 A EC SP10010538A
Authority
EC
Ecuador
Prior art keywords
oral disintegration
fine granules
solid oral
solid preparation
preparation
Prior art date
Application number
EC2010010538A
Other languages
English (en)
Inventor
Takashi Kurasawa
Yasuko Watanabe
Yoshihiro Omachi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40791576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP10010538A publication Critical patent/ECSP10010538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion provee una preparacion solida de desintegracion oral tales como un comprimido producido formando comprimidos los granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico y un aditivo, y similares, y la preparacion solida de desintegracion oral que contiene granulos finos recubiertos con una capa de recubrimiento que contiene un polimero que produce una pelicula de recubrimiento que tiene una elongacion en la ruptura de alrededor de 100 - alrededor de 700%. Con la preparacion, la ruptura de los granulos finos durante la formacion del comprimido puede suprimirse en la produccion de una preparacion solida de desintegracion oral que contiene los granulos finos que muestran una liberacion controlada de un principio activo para uso farmaceutico.
EC2010010538A 2008-03-11 2010-10-11 Preparacion solida de desintegracion oral ECSP10010538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008061673 2008-03-11
JP2008334920 2008-12-26

Publications (1)

Publication Number Publication Date
ECSP10010538A true ECSP10010538A (es) 2010-11-30

Family

ID=40791576

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010538A ECSP10010538A (es) 2008-03-11 2010-10-11 Preparacion solida de desintegracion oral

Country Status (26)

Country Link
US (2) US9241910B2 (es)
EP (1) EP2254556A2 (es)
JP (1) JP5604304B2 (es)
KR (1) KR20100129761A (es)
CN (2) CN104127368A (es)
AR (1) AR070863A1 (es)
AU (1) AU2009224254A1 (es)
BR (1) BRPI0909439A2 (es)
CA (1) CA2717947C (es)
CL (1) CL2009000557A1 (es)
CO (1) CO6321224A2 (es)
CR (1) CR11709A (es)
DO (1) DOP2010000273A (es)
EA (1) EA021792B1 (es)
EC (1) ECSP10010538A (es)
GE (1) GEP20135845B (es)
IL (1) IL207989A0 (es)
MA (1) MA32174B1 (es)
MX (1) MX2010009824A (es)
MY (1) MY173730A (es)
NZ (1) NZ588407A (es)
PE (2) PE20091620A1 (es)
TW (1) TWI441658B (es)
UY (1) UY31698A (es)
WO (1) WO2009113703A2 (es)
ZA (1) ZA201006679B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
RU2011102777A (ru) * 2008-06-26 2012-08-10 МакНЕЙЛ-ППС, ИНК. (US) Частицы с покрытием, содержащие фармацевтически активные агенты
US8303868B2 (en) 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20130216617A1 (en) * 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
TW201304823A (zh) * 2010-12-27 2013-02-01 Takeda Pharmaceutical 口腔內崩壞錠
CN102716097A (zh) * 2012-05-29 2012-10-10 浙江华海药业股份有限公司 控制口腔崩解片药物释放速率的方法
FI126168B (en) * 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016129140A1 (ja) * 2015-02-10 2016-08-18 富士フイルム株式会社 口腔内崩壊錠及びその製造方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6905972B2 (ja) * 2016-02-23 2021-07-21 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
EP3419659A1 (en) 2016-02-23 2019-01-02 The Regents of the University of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
GB201607548D0 (en) 2016-04-29 2016-06-15 Univ Central Lancashire Solid dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
WO2018124284A1 (ja) * 2016-12-28 2018-07-05 富山化学工業株式会社 医薬組成物
KR102555664B1 (ko) * 2017-02-21 2023-07-18 이에이 파마 가부시키가이샤 과립 제제
JP7235193B2 (ja) * 2017-04-26 2023-03-08 大正製薬株式会社 固形組成物
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物
WO2019143744A1 (en) 2018-01-16 2019-07-25 Applied Materials, Inc. Metal oxide encapsulated drug compositions and methods of preparing the same
MX2020007817A (es) 2018-01-24 2020-09-25 Purdue Pharma Lp Prevención y tratamiento del trastorno del sueño.
WO2019156904A1 (en) * 2018-02-08 2019-08-15 Taiwanj Pharmaceuticals Co., Ltd. Pharmaceutical formulation for a solid dosage form of opioid receptor antagonists
EP3917621A1 (en) 2019-01-31 2021-12-08 Purdue Pharma LP Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
KR20220051250A (ko) 2019-08-27 2022-04-26 어플라이드 머티어리얼스, 인코포레이티드 약제 남용 억제 제형들을 위한 증기상 코팅 기술
TW202122111A (zh) 2019-08-27 2021-06-16 美商應用材料股份有限公司 用於藥物溶解度控制之氣相塗層
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
CN112121067A (zh) * 2020-11-16 2020-12-25 深圳科兴药业有限公司 一种婴儿型双歧杆菌微胶囊及其制备方法
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
EP4340837A4 (en) 2021-05-21 2025-04-09 Purdue Pharma L.P. METHODS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
US12629380B2 (en) 2021-08-25 2026-05-19 Swipp Ab Oral film unit dosage form
WO2023056304A1 (en) 2021-09-30 2023-04-06 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications
JPWO2023182332A1 (es) * 2022-03-22 2023-09-28
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
IL326884A (en) 2023-10-19 2026-04-01 Purdue Pharma Lp Sunobinop for use in method of treating alcohol use disorder
CN117180213B (zh) * 2023-10-23 2026-08-11 湖南洞庭药业股份有限公司 奥沙西泮片组合物及其制备和稳定化方法
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CN117860699A (zh) * 2024-01-07 2024-04-12 长沙晶易医药科技股份有限公司 一种细粒剂及其制备方法
KR20260019740A (ko) * 2024-08-02 2026-02-10 일양약품주식회사 일라프라졸, 제산제 및 알칼리화제를 포함하는 안정한 약제학적 조성물 및 이의 제조방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
ES2237121T3 (es) 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
JP5502254B2 (ja) 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
EP1416922A1 (en) * 2001-07-16 2004-05-12 AstraZeneca AB Pharmaceutical formulation comprising a proton pump inhibitor and antacids
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
US20040096497A1 (en) 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
US20060115529A1 (en) * 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
JP2007524646A (ja) 2003-07-17 2007-08-30 ドクター レディズ ラボラトリーズ， インコーポレイテッド 膨潤可能なコーティングを有する薬学的組成物
NZ546183A (en) 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
GB0323232D0 (en) * 2003-10-03 2003-11-05 Rolls Royce Plc Electrical machine
WO2005079752A2 (en) 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20050214371A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
CA2557634A1 (en) 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited Stable capsule preparation
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
DE102004035936A1 (de) * 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
CN101115469A (zh) 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
GB0502479D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
FR2885526B1 (fr) 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
EA015535B1 (ru) 2005-07-11 2011-08-30 Никомед Данмарк Апс Формуляция бензимидазола
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1962844A2 (en) 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US20070141151A1 (en) 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
JP2009519334A (ja) * 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
KR100762847B1 (ko) 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
EP1837016A3 (en) 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
WO2007122478A2 (en) 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
AU2007242077B2 (en) 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US8747920B2 (en) 2006-04-28 2014-06-10 Wockhardt Ltd. Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic-analgesic drug and proton pump inhibitor
JP2009541337A (ja) 2006-06-19 2009-11-26 マクニール−ピーピーシー・インコーポレーテツド 活性成分を含有する腸溶性の被覆された粒子
EP2040684B1 (en) 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
AU2007276874B2 (en) 2006-07-28 2010-08-19 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
EP2063872B2 (en) * 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
PL2152250T3 (pl) 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
WO2010008569A1 (en) 2008-07-17 2010-01-21 Barr Laboratories, Inc. Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same
TW201304823A (zh) 2010-12-27 2013-02-01 Takeda Pharmaceutical 口腔內崩壞錠

Also Published As

Publication number Publication date
DOP2010000273A (es) 2010-09-30
WO2009113703A3 (en) 2010-06-17
EA021792B1 (ru) 2015-09-30
JP5604304B2 (ja) 2014-10-08
UY31698A (es) 2009-11-10
AU2009224254A1 (en) 2009-09-17
KR20100129761A (ko) 2010-12-09
CA2717947C (en) 2020-07-07
US20150037423A1 (en) 2015-02-05
IL207989A0 (en) 2010-12-30
JP2011513204A (ja) 2011-04-28
US9241910B2 (en) 2016-01-26
GEP20135845B (en) 2013-06-10
ZA201006679B (en) 2011-11-30
NZ588407A (en) 2012-07-27
MA32174B1 (fr) 2011-03-01
AU2009224254A2 (en) 2010-11-18
TW200944249A (en) 2009-11-01
AR070863A1 (es) 2010-05-12
CN102026627B (zh) 2016-10-26
BRPI0909439A2 (pt) 2015-12-15
WO2009113703A2 (en) 2009-09-17
CN102026627A (zh) 2011-04-20
EA201071054A1 (ru) 2011-04-29
MY173730A (en) 2020-02-18
US20110091563A1 (en) 2011-04-21
TWI441658B (zh) 2014-06-21
MX2010009824A (es) 2010-09-28
CN104127368A (zh) 2014-11-05
PE20141034A1 (es) 2014-09-10
PE20091620A1 (es) 2009-11-12
CR11709A (es) 2010-11-04
CL2009000557A1 (es) 2010-10-01
EP2254556A2 (en) 2010-12-01
CA2717947A1 (en) 2009-09-17
CO6321224A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
DOP2010000273A (es) Preparacion solida de desintegracion oral
CU20130094A7 (es) Moduladores de la vía del complemento
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PE20080765A1 (es) Formas de dosificacion farmaceutica
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
NZ709958A (en) Enhanced stability of novel liquid compositions
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
SG10201811365RA (en) Slow-release conjugates of sn-38
PH12016500693A1 (en) Slow-release solid oral compositions
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
CL2009001062A1 (es) Mezcla de barniz para revestir una forma farmaceutica de dosificacion solida que comprende a) agua (80 a 99% del peso total), b) un agente formador de pelicula (0,25 a 20% del peso total), y c) un agente de revestimiento (0,01 a 5% del peso total;) proceso de barnizado; forma farmaceutica solida .
PH12016501756B1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
PH12015501294A1 (en) A combination medicament comprising phenylephrine and paracetamol
GT200700005A (es) Composicion farmaceutica estable de carisoprodol y meloxicam
UA102010C2 (ru) Комбинация активных ингредиентов, которая содержит нестероидное противовоспалительное лекарственное средство и производное колхикозида
CO6680616A2 (es) Compuestos de tiofeno 2.3.5- trisustituidos y usos de los mismos
CR20110394A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antiinflamatorio, no esteroideo y un derivado de colchicosido
DOP2011000238A (es) Nueva asociacion de ingredientes activos que contienen un farmaco antinflamatorio, no esteroideo y un derivado de colchicosido
PH12018550075A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
CO6410294A2 (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido
UA88462U (ru) Твердая лекарственная форма препарата седативного и снотворного действия
TN2010000411A1 (en) Orally-disintegrating solid preparation